EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ms4a4a deficiency ameliorates plaque pathology in a mouse model of amyloid accumulation

Emma P Danhash, Anthony C Verbeck, Daniel Western, Andrea S Díaz-Pacheco, Grant Galasso, Shih-Feng You, Guangming Huang, Emma Starr, Nadia Miller, Collin J Nadarajah, Savannah Tiemann Powles, Erik S Musiek und 5 weitere

Alzheimer's & Dementia · 2025-08 · 21 (8)

DOI: 10.1002/alz.70580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 22.08.2025. Verfasst von Emma P Danhash und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Plaque, Amyloid, Alzheimer Disease, Amyloid beta-Peptides, Brain. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, Edward N. and Della L. Thome Memorial Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Genome‐wide association studies have identified MS4A4A , a microglia‐enriched gene, as a modulator of Alzheimer's disease (AD) risk. Common variants in MS4A4A affect AD susceptibility, gene expression, triggering receptor expressed on myeloid cells 2 (TREM2) signaling, and microglial transcriptional states, but the gene's functional role remains unclear. METHODS Using a novel model, we investigated the impact of Ms4a4a loss in the 5xFAD mouse model of amyloid beta (Aβ) accumulation. RESULTS Ms4a4a deficiency reduced steady‐state Aβ levels and shortened its half‐life in brain interstitial fluid. Aged 5xFAD mice lacking Ms4a4a exhibited more compact plaques and lower overall plaque burden. Microglia deficient in Ms4a4a showed a pro‐inflammatory profile and elevated matrix metalloproteinase 9 (MMP‐9) production, which may facilitate Aβ degradation. Notably, human carriers of the AD‐resilient variant rs1582763 near MS4A4A also displayed increased cerebrospinal fluid MMP‐9 levels. DISCUSSION Together, we show that Ms4a4a loss enhances Aβ clearance and reduces pathology, suggesting a protective mechanism that may inform microglia‐targeted AD therapies. Highlights We examined the impact of Ms4a4a loss on amyloid beta (Aβ) pathology using a mouse model of Aβ accumulation (5xFAD). Ms4a4a loss reduces overall plaque burden and increases plaque compaction. Microglia lacking Ms4a4a are more pro‐inflammatory and produce more matrix metalloproteinase 9 (MMP‐9). Alzheimer's disease (AD) resilience variant carriers, MS4A4A rs1582763, exhibit significantly elevated levels of cerebrospinal fluid MMP‐9. Our findings suggest that reduction of MS4A4A may be a therapeutic approach for AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plaque, AmyloidAlzheimer DiseaseAmyloid beta-PeptidesBrainAnimalsDisease Models, AnimalMiceMicrogliaMice, TransgenicMatrix Metalloproteinase 9Humans

Stichwörter der Autor:innen

Alzheimer's diseaseMS4A4Aamyloid beta clearanceanimal modelmicrogliaresilience

Substanzen

Amyloid beta-PeptidesMatrix Metalloproteinase 9

Autor:innen und Institutionen

  • Department of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
  • Department of Neurology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
  • Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • Edward N. and Della L. Thome Memorial Foundation
  • Washington University
  • Hope Center for Neurological Disorders
  • NCATS NIH HHS
  • NIH HHS
  • The recruitment and clinical characterization of Knight

Zitieren

APA

Danhash, E. P., Verbeck, A. C., Western, D., Díaz-Pacheco, A. S., Galasso, G., You, S. F., Huang, G., Starr, E., Miller, N., Nadarajah, C. J., Tiemann Powles, S., Musiek, E. S., Herz, J., Iyer, A. K., Cirrito, J., Cruchaga, C., & Karch, C. M. (2025). Ms4a4a deficiency ameliorates plaque pathology in a mouse model of amyloid accumulation. Alzheimer's & Dementia, 21(8). https://doi.org/10.1002/alz.70580

Vancouver

Danhash EP, Verbeck AC, Western D, Díaz-Pacheco AS, Galasso G, You SF, et al. Ms4a4a deficiency ameliorates plaque pathology in a mouse model of amyloid accumulation. Alzheimer's & Dementia. 2025;21(8). doi:10.1002/alz.70580

BibTeX
@article{Danhash2025,
  author = {Danhash, Emma P and Verbeck, Anthony C and Western, Daniel and Díaz-Pacheco, Andrea S and Galasso, Grant and You, Shih-Feng and Huang, Guangming and Starr, Emma and Miller, Nadia and Nadarajah, Collin J and Tiemann Powles, Savannah and Musiek, Erik S and Herz, Jasmin and Iyer, Abhirami K and Cirrito, John and Cruchaga, Carlos and Karch, Celeste M},
  title = {Ms4a4a deficiency ameliorates plaque pathology in a mouse model of amyloid accumulation},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {8},
  doi = {10.1002/alz.70580}
}
Kostenlos starten →